Safety and Tolerability of the MAO Inhibitor Isocarboxazid (Marplan) in the prophylactic treatment o...
Download
1 / 16

Herbert Harris, MD, PhD Validus Pharmaceuticals, Parsippany, New Jersey Bruce Corser, MD - PowerPoint PPT Presentation


  • 108 Views
  • Uploaded on

Safety and Tolerability of the MAO Inhibitor Isocarboxazid (Marplan) in the prophylactic treatment of migraine*. Herbert Harris, MD, PhD Validus Pharmaceuticals, Parsippany, New Jersey Bruce Corser, MD Community Research, Cincinnati, Ohio Richard A Guarino, MD

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Herbert Harris, MD, PhD Validus Pharmaceuticals, Parsippany, New Jersey Bruce Corser, MD' - lihua


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Herbert harris md phd validus pharmaceuticals parsippany new jersey bruce corser md
Safety and Tolerability of the MAO Inhibitor Isocarboxazid (Marplan) in the prophylactic treatment of migraine*

  • Herbert Harris, MD, PhD

    • Validus Pharmaceuticals, Parsippany, New Jersey

  • Bruce Corser, MD

    • Community Research, Cincinnati, Ohio

  • Richard A Guarino, MD

    • Oxford Pharmaceutical Services, Totowa, New Jersey

      * Study funded by Validus Pharmaceuticals


Migraine prophylaxis
Migraine prophylaxis (Marplan) in the prophylactic treatment of migraine*

  • antiepileptic agents

    • topiramate and divalproex

  • beta-adrenergic blockers

    • propranolol and timolol.

  • methysergide (withdrawn)

  • antidepressants

    • tricyclic antidepressants


Objective

Objective (Marplan) in the prophylactic treatment of migraine*

The purpose of this open-label pilot study was to evaluate the safety and tolerability of the MAOI Isocarboxazid (Marplan) in the prophylactic treatment of migraine.


Methods
Methods (Marplan) in the prophylactic treatment of migraine*

  • Male and female subjects 18-60 years of age

  • Diagnosis of migraine according to IHS criteria

  • 3-12 HAs per month for the 3 months prior to screening

  • Isocarboxazid (Marplan) treatment was initiated at 20mg per day and increased as tolerated to a maximum dose of 60mg per day

  • Treatment covered three months

  • Concomitant use of tryptans, NSAIDs antidepressants and other commonly used anti-migraine agents was prohibited

  • The primary efficacy measure was within-subject change from baseline in migraine frequency.


Study population
Study Population (Marplan) in the prophylactic treatment of migraine*


Demographics
Demographics (Marplan) in the prophylactic treatment of migraine*


Safety and tolerability
Safety and Tolerability (Marplan) in the prophylactic treatment of migraine*


Discontinuations due to aes
Discontinuations due to AEs (Marplan) in the prophylactic treatment of migraine*


Maximum tolerated dose
Maximum Tolerated Dose (Marplan) in the prophylactic treatment of migraine*


Isocarboxazid doses in study
Isocarboxazid (Marplan) in the prophylactic treatment of migraine*Doses in Study


Other treatment emergent aes
Other Treatment Emergent AEs (Marplan) in the prophylactic treatment of migraine*


Efficacy
Efficacy (Marplan) in the prophylactic treatment of migraine*


Average migraine frequency completers
Average Migraine Frequency (Completers) (Marplan) in the prophylactic treatment of migraine*


Responders
Responders (Marplan) in the prophylactic treatment of migraine*


Observed cases and locf
Observed Cases and LOCF (Marplan) in the prophylactic treatment of migraine*


Conclusions
Conclusions (Marplan) in the prophylactic treatment of migraine*

  • The tolerability of Isocarboxazid (Marplan) in this study was similar to that reported in depression trials

    • Insomnia, irritability, and sexual dysfunction were the most common adverse events

    • Five subjects (31%) withdrew due to adverse events

    • No serious adverse events were reported

  • In this small open-label study, Isocarboxazid (Marplan) showed very robust clinical efficacy in the prophylactic treatment of migraine attacks

  • Isocarboxazid offers a mechanistically novel approach to migraine prophylaxis that warrants further investigation.